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exert luteotrophic actions, apparently via the cAMP signalling
pathway. In addition to stimulating progesterone synthesis,
PGE2 can also stimulate oxidation of the physiological
glucocorticoid, cortisol, to its inactive metabolite, cortisone,
by the type 1 11b-hydroxysteroid dehydrogenase (11bHSD1)
enzyme in human granulosa–lutein cells. Having previously
shown these human ovarian cells to express functional
G-protein coupled, E-series prostaglandin (PTGER)1,
PTGER2 and PTGER4 receptors, the aim of this study
was to delineate the roles of PTGER1 and PTGER2
receptors in mediating the effects of PGE2 on steroidogenesis
and cortisol metabolism in human granulosa–lutein cells.
PGE2-stimulated concentration-dependent increases in both
progesterone production and cAMP accumulation (by 1.9G
0.1- and 18.7G6.8-fold respectively at 3000 nM PGE2).
While a selective PTGER1 antagonist, SC19220, could
partially inhibit the steroidogenic response to PGE2 (byThis is an Open Access article distributed under the terms of the Society for Endo
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a mixed PTGER1/PTGER2 receptor antagonist, completely
abolished the stimulation of progesterone synthesis at all tested
concentrations of PGE2 and suppressed the stimulation of
cAMP accumulation. Both PGE2 and butaprost (a preferential
PTGER2 receptor agonist) stimulated concentration-depen-
dent increases in cortisol oxidation by 11bHSD1 (by 42.5G
3.1 and 40.0G3.0% respectively, at PGE2 and butaprost
concentrations of 1000 nM). Co-treatment with SC19220
enhanced the ability of both PGE2 and butaprost to stimulate
11bHSD1 activity (by 30.2G0.2 and 30.5G0.6% respect-
ively), whereas co-treatment with AH6809 completely
abolished the 11bHSD1 responses to PGE2 and butaprost.
These findings implicate the PTGER2 receptor–cAMP
signalling pathway in the stimulation of progesterone
production and 11bHSD1 activity by PGE2 in human
granulosa–lutein cells.
Journal of Endocrinology (2007) 194, 595–602Introduction
Prostaglandins (PGs) have been implicated in the co-ordi-
nation of ovarian function, particularly in ovulation and in
regulating the functional lifespan of the corpus luteum. For
example, PGF2a has luteolytic effects and can trigger
functional luteal regression in a range of species, including
humans and non-human primates (reviewed by Michael et al.
1994, Olofsson & Leung 1994), whereas selected PGs, like
PGE2, can exert luteotrophic actions in human and non-
human primate ovarian cells, stimulating progesterone
synthesis apparently via the cAMP signalling pathway
(Richardson 1986, Michael et al. 1993, 1994, Olofsson &Leung 1994). Although PGs are established as major paracrine
agents in ovarian physiology, their exact modes of action still
remain to be elucidated.
Glucocorticoid steroids are also known to be important for
gonadal function and have been implicated in the control of
oocyte maturation (Greeley et al. 1986, Harlow et al. 1997,
Yang et al. 1999, Chen et al. 2000). In potential target tissues,
the physiological glucocorticoids, cortisol and corticosterone,
are oxidised to inert metabolites (cortisone and 11-dehy-
drocorticosterone respectively) by 11b-hydroxysteroid
dehydrogenase (11bHSD) enzymes (Seckl & Walker 2001,
Seckl 2004, Draper & Stewart 2005). These enzymes are
expressed and appear to play significant physiological roles incrinology’s Re-use Licence which permits unrestricted non-commercial use,
erly cited.
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C CHANDRAS and others . PTGER1 receptors and PGE2 actions596reproductive tissues (reviewed by Michael et al. (2003)). For
example, in the uterine–placental complex, both the
relatively low-affinity NADP(H)-dependent type 1
11bHSD enzyme (11bHSD1) and the high-affinity
NADC-dependent type 2 11bHSD enzyme (11bHSD2)
have recently been implicated in the physiological mechanism
of labour (Challis et al. 2000, Whittle et al. 2001), although
prior studies of human placenta and decidua had found no
significant changes in cortisol metabolism by 11bHSD at
parturition (Lo´pez Bernal et al. 1982a,b).
Previously, we have established that luteinizing human
granulosa cells, recovered from the ovarian follicular aspirates
of women undergoing oocyte retrieval for in vitro fertilisation,
exclusively express 11bHSD1 with no detectable expression
of 11bHSD2 at either the mRNA or the protein level
(Michael et al. 1997, Thurston et al. 2003a). Although
11bHSD1 generally acts as a 11-ketosteroid reductase to
regenerate cortisol from cortisone (Seckl & Walker 2001,
Seckl 2004, Draper & Stewart 2005), we have previously
reported that in intact human granulosa–lutein cells in
primary culture, 11bHSD1 acts predominantly as a 11b-
dehydrogenase enzyme to catalyse the oxidative inactivation
of cortisol (Michael et al. 1997, Thurston et al. 2003a). Since
the utero-placental feedback loop for the induction of
parturition (at least in sheep) appears to require stimulation
of 11bHSD1 by PGs (Alfaidy et al. 2001, Challis et al. 1997),
we have investigated the possible role for local PGs in control
of 11bHSD1 in human granulosa–lutein cells in vitro. We
recently reported that inhibition of local PG synthesis (using
four structurally distinct inhibitors of PGH synthase) could
suppress cortisol oxidation by 11bHSD1 in these human cells,
but that this enzyme activity could be stimulated by PGE2
(Jonas et al. 2006).
At the cellular level, PGE2 actions are mediated through G
protein-coupled,E-series PG (PTGER) receptors. To date, four
subtypes of PTGER receptors have been cloned, designated
PTGER1, PTEGER2, PTGER3 and PTGER4 (Hirata et al.
1991, Sugimoto et al. 1992, Funk et al. 1993, Honda et al. 1993,
Watabe et al. 1993), with multiple isoforms of the PTGER3
receptor subtype (reviewed by Coleman et al. (1994)). While
PTGER1 and PTGER3 receptors mediate increases in
intracellular calcium concentrations, PTGER2 and PTGER4
receptors mediate stimulation of intracellular cAMP accumu-
lation (Narumiya et al. 1999). Since PTGER receptors have
different affinities for synthetic PGE2 analogues, agonists and
antagonists with differing degrees of preference or selectivity for
each PTGER receptor subtype can be used to delineate the role
for particular PTGER receptors in a given cellular response
(Coleman et al. 1994). Using RT-PCR and preferential receptor
agonists/antagonists, we and other researchers have established
that human granulosa–lutein cells express PTGER1, PTGER2
and PTGER4 receptors, and that the PTGER1 and PTGER2
receptors are able to elicit increases in intracellular calcium and
cAMP respectively (Harris et al. 2001, Narko et al. 2001).
However, the exact PG receptors through which PGE2 exerts its
effects on progesterone synthesis and cortisol–cortisoneJournal of Endocrinology (2007) 194, 595–602interconversion by 11bHSD1 have not been previously
examined in ovarian cells. Hence, the aim of the current study
was to examine the potential roles for PTGER1 and PTGER2
receptors in mediating the effects of PGE2 on steroidogenesis
and cortisol metabolism using human granulosa–lutein cells as
our in vitro ovarian model.Materials and Methods
Isolation and culture of human granulosa cells
Human granulosa cells were isolated from follicular aspirates
of women undergoing controlled ovarian hyperstimulation
for assisted conception at the Lister Private Hospital (Chelsea,
London, UK) as previously described by Webley et al. (1988).
Follicular aspirates were collected with informed patient
consent in accordance with the Declaration of Helsinki and as
approved by the local ethics committee.
Following isolation on 60% (v/v) Percoll, human granulosa–
lutein cells were cultured for 48 h in 1:1 Dulbecco’s modified
Eagle’s medium (DMEM):Ham’s F12 medium supplemented
with 10% (v/v) fetal calf serum (Invitrogen Life Technologies),
2 mM L-glutamine (Life Technologies), penicillin (87 000 IU/l;
Sigma–Aldrich) and streptomycin (87 mg/l; Sigma–Aldrich) in
an atmosphere of 5% (v/v) CO2 in air. Cells were cultured either
in 250 ml volumes at a density of 1!105 viable cells/well for
assessing regulation of progesterone production and cAMP
accumulation or in 1 ml volumes at a density of 5!104 viable
cells/well in 24-well plates for measurement of 11bHSD1
activities. For all experiments, cell viability, assessed byexclusion
of 0.4% (v/v) trypan blue dye, was consistentlyO85%.Concentration-dependent effects of PGE2 on progesterone
production and cAMP accumulation in the absence or presence of
SC19220 and AH6809
In order to examine whether PTGER2 receptors were involved
in mediating the steroidogenic response to PGE2, cells were
transferred to serum-free 1:1 DMEM:Ham’s F12 medium
supplemented with 1 mM meclofenamic acid (Sigma–Aldrich)
to suppress intrinsic PG synthesis ( Jonas et al. 2006). Cells
were challenged for 24 h with a range of PGE2 concentrations
(0–3000 nM; Cayman Chemical Company, MI, USA) in the
absence and presence of either 10 mM SC19220 or 10 mM
AH6809 (Alexis Biochemicals, Nottingham, UK). SC19220
and AH6809 were prepared to a stock concentration of 10 mM
in dimethylsulphoxide (DMSO), the final concentration of
which was diluted in all wells to 0.1% by volume.
After the 24-h treatment period, culture plates were frozen
at K20 8C. Samples were subsequently thawed and pro-
gesterone and cAMP concentrations were measured using
RIAs previously described by Pallikaros et al. (1995) and
Steiner et al. (1972) respectively. The progesterone RIA had a
working range of 0.5–8.0 nM with inter- and intra-assay
coefficients of variation of 9 and 14% respectively. The cAMPwww.endocrinology-journals.org
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Brooker (1975), which gave the assay a working range of 0.2–
1.3 nM with inter- and intra-assay coefficients of variation of
9 and 5% respectively.Table 1 Effects of SC19220 and AH6809 on basal progesterone
production and 11b-hydroxysteroid dehydrogenase (11bHSD1)
activity. Values are the meanGS.E.M. for three independent
experiments with quadruplicate determinations in each experiment
(one-way ANOVA)Effects of SC19220 and AH6809 on 11bHSD1 activities in
response to PGE2 and butaprost in human granulosa–lutein cells
As in the assessment of the effects on progesterone production
and cAMP accumulation, cells were pre-incubated for 48 h in
serum-supplemented 1:1 DMEM:Ham’s F12 medium.
Following this, the cells were transferred to serum-free 1:1
DMEM:Ham’s F12 medium, supplemented with 1 mM
meclofenamic acid and containing PGE2 or butaprost
(Cayman Chemical Company; 0–1000 nM of each), each in
the absence or presence of 10 mM SC19220 or AH6809 for
4 h. To overcome potential confounding effects of pro-
gesterone on 11bHSD activities (Thurston et al. 2003b), these
experiments were performed in the presence of 100 mM
aminoglutethimide, having confirmed that this effectively
suppresses progesterone output from human granulosa–lutein
cells (Fowkes et al. 2001) without affecting cAMP accumu-
lation. During the 4 h over which cells were exposed to
PGE2/butaprostGSC19220/AH6809, 11bHSD1 activities
were assessed using the radiometric conversion assay as
previously described by Michael et al. (1995). In brief, intact
cells in primary culture were co-incubated with 100 nM
[1,2,6,7-3H]-cortisol (Amersham Biosciences), diluted to a
specific activity of 0.5 mCi/100 pmol using non-radiolabelled
cortisol (Sigma–Aldrich). At the end of the 4-h treatment
period, spent culture medium was transferred to screw cap
borosilicate tubes in which steroids were extracted by the
addition of two volumes of chloroform (Merck). After
evaporation to dryness under nitrogen gas at 45 8C, the
steroid residues were suspended in 25 ml ethyl acetate
containing 1 mM cortisol and 1 mM cortisone (Sigma–
Aldrich) before being resolved by thin layer chromatography
(TLC) on silica 60 TLC plates (Merck), developed in an
atmosphere of 92:8 chloroform:95% (v/v) ethanol. [3H]-
cortisol and [3H]-cortisone were quantified using a Bioscan
200 TLC radiochromatogramme scanner (Lablogic, Sheffield,
UK) and the oxidative activities of 11bHSD1 were calculated
as net pmoles cortisol oxidised to cortisone over 4 h (Michael
et al. 1995).Progesterone
(pmol/105 cells)
11bHSD1 activity
(pmol cortisone/4 h .5
!104cells)
Control 2351.1G1028.3 3.7G1.2
CSC19220 2041.6G913.6 3.8G1.1
CAH6809 2712.5G1318.1 2.5G0.4
ANOVA PZ0.161 PZ0.158
Progesterone concentrations in culture medium and 11bHSD1 activities in
human granulosa–lutein cells were each assessed following a 24- or 4-h
incubation respectively with 10 mM SC19220 or 10 mM AH6809.Statistical analyses
All experimental data are presented as the meanGS.E.M. for
up to six independent experiments, where each experimental
replicate was performed using cells from individual patients
and each experimental condition was repeated either in
quadruplicate or in triplicate within an experiment. Due to
differences in absolute levels of progesterone production,
cAMP accumulation and enzyme activities between patients,
the results for each experiment were standardised andwww.endocrinology-journals.orgpresented as a percentage of basal control. However, all
statistical analyses were performed using absolute data.
In all experiments, a one-way ANOVA with repeated
measures was performed, followed by Bonferroni’s multiple
comparison as the post hoc test. All statistical evaluations were
performed using GraphPad Prism version 3.02 (GraphPad
Software Inc., San Diego, CA, USA) and significance was
assessed in all experiments as a probability value of P!0.05.Results
Effects of SC19220 and AH6809 on progesterone production
and 11bHSD1 activity
Before use, both PTGER receptor antagonists were tested for
possible direct effects on basal progesterone production and
11bHSD1 activity in human granulosa–lutein cells. Under
conditions in which intrinsic PG synthesis had been
suppressed with 1 mM meclofenamic acid, incubation for
24 h with the preferential PTGER1 receptor antagonist
SC19220 (10 mM) and the PTGER1/PTGER2 receptor
antagonist AH6809 (10 mM) had no significant effect on basal
progesterone production (over 24 h) or the oxidative activity
of 11bHSD1 (over 4 h; Table 1).Concentration-dependent effects of PGE2 on progesterone
production in the absence or presence of SC19220 and
AH6809
Treatment with PGE2 for 24 h resulted in a concentration-
dependent increase in progesterone synthesis (Fig. 1). At
PGE2 concentrations R30 nM, progesterone production
increased progressively by up to 91G6% (at 3000 nM
PGE2) relative to the control rate of progesterone output in
the absence of PGE2 (P!0.01). However, co-treatment with
SC19220 attenuated the responses to both 1000 and 3000 nM
PGE2 by 56G4% (P!0.001) and 35G3% (P!0.001)
respectively, while co-treatment with AH6809 completelyJournal of Endocrinology (2007) 194, 595–602
Figure 2 Effects of SC19220 and AH6809 on the cAMP responses to
PGE2 by human granulosa–lutein cells. Concentrations of cAMP
after a 24-h incubation in the presence of 0–3000 nM PGE2, either
in the absence (circle) or in the presence of 10 mM SC19220
(square) or 10 mM AH6809 (triangle). Values are the meanGS.E.M.
for three independent experiments with quadruplicate determina-
tions in each experiment. *P!0.05, **P!0.01 relative to 0 nM
PGE2 in the absence or presence of the PTGER receptor antagonists,
as appropriate (one-way ANOVA plus Bonferroni’s post hoc
multiple comparison test).
Figure 1 Effects of SC19220 and AH6809 on the progesterone
responses to PGE2 by human granulosa–lutein cells. Progesterone
concentrations in medium collected after a 24-h incubation in the
presence of 0–3000 nM PGE2, either in the absence (circle) or in the
presence of 10 mM SC19220 (square) or 10 mM AH6809 (triangle).
Values are the meanGS.E.M. for three independent experiments with
quadruplicate determinations in each experiment. *P!0.05,
**P!0.01, ***P!0.001 relative to 0 nM PGE2 in the absence or
presence of the PTGER receptor antagonist, as appropriate.
aP!0.05, cP!0.001 relative to cells treated with the same PGE2
concentration in the absence of PTGER receptor antagonists (one-
way ANOVA plus Bonferroni’s post hoc multiple comparison test).
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progesterone output.
Incubation for 24 h with PGE2 evoked a concentration-
dependent increase in cAMP accumulation which only
achieved significance at the supraphysiological concentrations
of 1000 and 3000 nM PGE2 (Fig. 2). At the highest tested
concentration of 3000 nM, PGE2 increased cAMP accumu-
lation by 18.7G6.8-fold (P!0.01) in the absence of PTGER
receptor antagonists. In cells co-treated with SC19220, this
maximal concentration of PGE2 increased cAMP accumu-
lation by 40.3G27.8-fold (P!0.01), whereas co-treatment
with AH6809 suppressed the cAMP response to 3000 nM
PGE2 to just 4.1G1.2-fold (P!0.05; Fig. 2).Effects of SC19220 and AH6809 on 11bHSD1 activities in
response to PGE2 and butaprost in human granulosa–lutein cells
Consistent with our recent report ( Jonas et al. 2006), PGE2
significantly increased 11bHSD1 activity in a concentration-
dependent manner; net oxidation of cortisol to cortisone was
increased by up to 43G3% at the highest tested PGE2
concentration of 1000 nM (P!0.001; Fig. 3). Co-treatment
with SC19220 further enhanced 11bHSD1 activities at each of
the tested concentrations of PGE2. At the highest tested
concentration of 1000 nM PGE2, co-treatment with SC19220
increased the 11bHSD1 activity by a further 32.7G10.2%
(P!0.05) relative to the cells treated with PGE2 in the absenceJournal of Endocrinology (2007) 194, 595–602of PTGER receptor antagonists. In contrast, co-treatment with
AH6809 completely abolished the 11bHSD1 response to all
tested concentrations of PGE2 (Fig. 3).
Incubation for 4 h with the preferential PTGER2 receptor
agonist butaprost also elicited a concentration-dependent
increase in 11bHSD1 activities (Fig. 4). At the highest tested
concentration of 1000 nM, butaprost increased net cortisol
oxidation by 40G3% (P!0.01). Co-treatment with SC19220
further increased 11bHSD1 activityat each tested concentration
of butaprost by up to 31G1% (P!0.05) relative to cells treated
with butaprost alone. In contrast, as for PGE2, co-treatment
with AH6809 completely abolished the stimulation of
11bHSD1 activities by each concentration of butaprost.Discussion
This study has investigated the potential participation of
PTGER1 and PTGER2 receptors in mediating the effects of
PGE2 on progesterone production and glucocorticoid
metabolism in human granulosa–lutein cells. Using prefer-
ential pharmacological agonists and antagonists for the
PTGER1 and PTGER2 receptor subtypes, the combined
data implicate PTGER2 receptors as mediators of the
stimulation of progesterone synthesis and 11bHSD1 activity
by PGE2 in this human ovarian cell model in vitro.
The ability of PGE2 to stimulate progesterone synthesis in
human and non-human primate luteal cells, and in the widely
used model of human granulosa–lutein cells, is well
documented (Hahlin et al. 1988, Fehrenbach et al. 1999,www.endocrinology-journals.org
Figure 3 Effects of PGE2 on 11bHSD1 activities human granulosa–
lutein cells in the absence and presence of SC19220 and AH6809.
11bHSD1 activities following treatment of cells with 0–1000 nM
PGE2 either in the absence (circle) or in the presence of 10 mM
SC19220 (square) or 10 mM AH6809 (triangle). Values are the
meanGS.E.M. for three independent experiments with triplicate
determinations in each experiment. *P!0.05, **P!0.01,
***P!0.001 relative to 0 nM PGE2 in absence or presence of the
PTGER receptor antagonists, as appropriate. aP!0.05, bP!0.01
relative to cells treated with the same PGE2 concentration in the
absence of PTGER receptor antagonists (one-way ANOVA plus
Bonferroni’s post hoc multiple comparison test).
Figure 4 Effects of butaprost on 11bHSD1 activities in human
granulosa–lutein cells in the absence and presence of SC19220 and
AH6809. 11bHSD1 activities following treatment of cells with 0–
1000 nM butaprost either in the absence (circle) or in the presence
of 10 mM SC19220 (square) or 10 mM AH6809 (triangle). Values are
the meanGS.E.M. for three independent experiments with triplicate
determinations in each experiment. *P!0.05, **P!0.01,
***P!0.001 relative to 0 nM butaprost in the absence or presence
of the PTGER receptor antagonists, as appropriate. aP!0.05,
bP!0.01 relative to cells treated with the same butaprost
concentration in the absence of PTGER receptor antagonists (one-
way ANOVA plus Bonferroni’s post hoc multiple comparison test).
PTGER1 receptors and PGE2 actions . C CHANDRAS and others 599
www.endocrinology-journals.orgVaananen et al. 2001). Given the reported ability of PGE2 to
increase intracellular cAMP concentrations in these cells
(Michael et al. 1993) and the established role for cAMP as a
second messenger that stimulates steroidogenesis (Cooke
1999), it has widely been assumed that the progesterone
response to PGE2 is mediated via this cyclic nucleotide. We
have previously demonstrated that both progesterone pro-
duction and cAMP accumulation in human granulosa–lutein
cells can be stimulated by the mixed PTGER1/PTGER2
receptor agonist, dimethyl-PGE2 and by the preferential
PTGER2 receptor agonist, butaprost (Harris et al. 2001).
The cAMP responses to dimethyl-PGE2 and butaprost
were completely abolished by co-treatment with the
PTGER1/PTGER2 receptor antagonist AH6809, but not
the selective PTGER1 receptor antagonist SC19220,
implicating the PTGER2 receptor in the cAMP response
to these pharmacological agonists (Harris et al. 2001).
Interestingly, the cAMP response to PGE2 was only partially
suppressed (by around 60%) with AH6809, and we did not
assess the ability of these compounds to interfere with the
steroidogenic responses to PGE2 or its functional analogues.
In the present study, when cells were co-treated with
SC19220, the progesterone response to PGE2 was partially
inhibited but not completely abolished. This suggests that the
PTGER1 receptors participate in the stimulation of
steroidogenesis by PGE2, but do not mediate the full
steroidogenic response. We have now confirmed that
co-treatment with AH6809 could completely prevent the
steroidogenic response to PGE2 at all tested concentrations,
implicating an AH6809-sensitive receptor in the steroido-
genic response to PGE2.
The concentrations of PGE2 (and butaprost) used for the
studies reported herein were selected based on previous
investigations of human granulosa–lutein cells, which
routinely use PGs at supraphysiological concentrations of
500–5000 nM. It is noteworthy that, at the lower tested
concentrations of 3 and 10 nM, PGE2 failed to stimulate
steroidogenesis, even though Abramovitz et al. (2000) have
previously reported that PGE2 concentrations of !30 nM
should be sufficient to stimulate all four PTGER receptor
subtypes. Moreover, although PGE2 and butaprost were able
to stimulate progesterone synthesis (and cortisol metabolism)
at concentrations of 30 nM and above, at these concen-
trations, PGE2 would be expected to saturate all four classes of
PTGER receptor and possibly to activate non-PTGER
receptors (i.e. PTGFR and D series prostaglandin (PTGDR)
receptors), particularly at the conventional concentrations of
300, 1000 and 3000 nM (Abramovitz et al. 2000). Since
PTGFR receptors are known to inhibit (rather than
stimulate) progesterone production (Sugimoto et al. 1997,
Tsai et al. 1998, 2001), it seems highly unlikely that the
steroidogenic response to PGE2 (even at concentrations O
30 nM) is mediated via the PTGFR receptor. However, we
cannot yet exclude participation of the PTGDR receptor in
the stimulation of steroidogenesis at high concentrations of
PGE2, given that AH6809 has also been reported to functionJournal of Endocrinology (2007) 194, 595–602
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10 mM (Keery & Lumley 1988, Woodward et al. 1995).
In terms of effects on cAMP accumulation, we found that
although PGE2 increased cAMP accumulation in a concen-
tration-dependent manner, this response only achieved
statistical significance at the higher concentrations of 1000
and 3000 nM PGE2, which would be expected to bind all
PTGER maximally, and possibly to activate PTGDR and
PTGFR receptors as well (Abramovitz et al. 2000).
Co-treatment of cells with AH6809 suppressed the PGE2-
induced increase in the cAMP accumulation, but did not
completely abolish the cAMP response to PGE2, indicating
that the residual effect of high PGE2 concentrations on cAMP
may be mediated through an AH6809-insensitive receptor.
SC19220, on the other hand, did not suppress the
responsiveness of the cells to PGE2. If anything, co-treatment
with the PTGER1 antagonist SC19220 enhanced the
increase of cAMP in response to PGE2. These observations
raise two possibilities. First, inhibition of PTGER1 receptor
binding by SC19220 may have facilitated increased binding of
PGE2 to other prostanoid receptors which are capable
of stimulating cAMP accumulation (e.g. PTGER2,
PTGER4 and/or PTGDR receptors). Secondly, co-stimula-
tion of the PTGER1 receptor would be expected to activate
the calcium–protein kinase C signalling pathway (Narumiya
et al. 1999), which can inhibit the stimulation of cAMP
production (Abayasekara et al. 1993a,b). Based on these
observations, prostanoid receptors which are sensitive to
AH6809 but insensitive to SC19220 (e.g. PTGER2 and/or
PTGDR) are implicated in the ability of PGE2 to stimulate
cAMP accumulation in human granulosa–lutein cells. In light
of our previous report (Harris et al. 2001), we would suggest
that while the ability of dimethyl-PGE2 and butaprost to
elevate intracellular cAMP concentrations is mediated solely
via a PG receptor that can be antagonised with AH6809,
consistent with a role for the PTGER2 receptor in eliciting a
cAMP response, at least some of the second messenger
response to PGE2 is mediated via AH6809-resistant receptors,
which may include PTGER4 receptors and possibly even
PTGDR receptors. We also note that, in the present study, the
residual cAMP responses to the higher concentrations of
PGE2 in cells co-treated with AH6809 were not accompanied
by any significant increases in progesterone synthesis, showing
that second messengers other than cAMP may be required for
PGE2 to stimulate steroidogenesis.
Turning to the regulation of cortisol–cortisone metabolism
by PGE2, we have previously established that luteinizing
human granulosa cells only express 11bHSD1 with no
detectable expression of 11bHSD2 protein or mRNA, even
when the PCR is used to increase the sensitivity of detection
(Michael et al. 1997, Thurston et al. 2003a). Although the
11bHSD1 enzyme is intrinsically bidirectional, in most tissues
this enzyme acts predominantly as an 11-ketosteroid reductase
to regenerate cortisol from cortisone (Seckl & Walker 2001,
Seckl 2004, Draper & Stewart 2005). However, we have
previously found that 11bHSD1 acts predominantly, if notJournal of Endocrinology (2007) 194, 595–602exclusively, to catalyse the oxidative inactivation of cortisol in
human granulosa–lutein cells (Michael et al. 1997, Thurston
et al. 2003a), bovine granulosa and luteal cells (Thurston et al.
2007) and porcine granulosa cells (Sunak et al. 2007).
11bHSD1 has also been reported to act predominantly as a
11b-dehydrogenase in rat testis Leydig cells (Gao et al. 1997,
Ge & Hardy 2000) suggesting that the major action of the
11bHSD1 enzyme may be fundamentally different in the
steroidogenic cells of the ovary and testis (Michael et al. 2003,
Ge et al. 2005). Recent studies have established that the
predominant direction of 11bHSD1 is dependent on the ratio
of the reduced form of nicotinamide adenine dinucleotide
phosphate to its oxidised form (NADPH: NADPC) within
the lumen of the smooth endoplasmic reticulum (Draper et al.
2003, Atanasov et al. 2004, Banhegyi et al. 2004, Bujalska et al.
2005, McCormick et al. 2006) such that changes in this ratio
in steroidogenic gonadal cells may favour the oxidative
activity of 11bHSD1 in these cells (Michael et al. 2003, Ge
et al. 2005).
In the present study, the stimulation of the net oxidation of
cortisol in human granulosa–lutein cells by PGE2 showed
good agreement with our recently published data (Jonas et al.
2006). The fact that this stimulation could be reproduced
using the preferential PTGER2 receptor agonist butaprost,
combined with the fact that AH6809 could completely
suppress the effects of PGE2 and butaprost on cortisol
oxidation, suggests that the stimulation of the oxidative
activity of 11bHSD1 is mediated via the PTGER2 receptor.
In contrast, co-treatment with SC19220 enhanced the
11bHSD1 response at each of the tested concentrations of
PGE2, suggesting that the co-activation of PTGER1
receptors limits the stimulation of cortisol–cortisone metab-
olism by PGE2. PTGER1 receptors are known to act via
calcium as a second messenger, and we have confirmed that in
human granulosa–lutein cells, SC19220 can antagonise the
ability of PGE2 and its dimethyl derivative to increase the
intracellular calcium concentration (Harris et al. 2001). Given
that studies of placental biochemistry have shown that calcium
can mediate the inhibition of 11bHSD1 activity in response
to PGs and leukotriene B4 (Hardy et al. 1999, 2001), we
would propose that activation of the PTGER1 receptor–
calcium signalling pathway by PGE2 limits the ability of this
PG to stimulate 11bHSD1 in human granulosa–lutein cells
via the PTGER2–cAMP pathway.
In comparing the three responses considered in this study,
we note that at the lower concentrations tested (!1000 nM),
which are likely to fall within the physiological range and
selectively to activate only the PTGER receptor subtypes,
PGE2 can stimulate both progesterone synthesis and cortisol
metabolism without exerting a significant effect on the
intracellular cAMP concentration. This suggests that either
the effects of 10–300 nM PGE2 on steroid synthesis and
metabolism are mediated via local increases in cAMP within
specific subcellular microenvironments (not reflected by
changes in the total intracellular cAMP concentration) orwww.endocrinology-journals.org
PTGER1 receptors and PGE2 actions . C CHANDRAS and others 601these effects are mediated via a second messenger other than
cAMP.
In summary, we have presented data which implicate
PTGER2 receptors in the stimulation of progesterone
synthesis, cAMP accumulation and cortisol metabolism via
11bHSD by PGE2 in human granulosa–lutein cells. Further
studies are necessary to elucidate potential roles for other
prostanoid receptors, such as PTGDR receptors, in the
responses at the upper concentrations of PGE2.Acknowledgements
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